MedTrace Logo

Induction of Dreaming With EEG and Anesthesia in Healthy Adults

NCT07198711 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-09-30

No results posted yet for this study

Summary

This open-label, randomized crossover study in healthy adults tests two propofol protocols to produce distinct experiential states. One induces brief loss of responsiveness with spontaneous emergence, intended to elicit dream reports; the other maintains light sedation without loss of responsiveness, intended to elicit non-dream experiences while participants remain responsive. The main goals are to (a) measure the protocol-concordant experiential report rate (how often each method produces its intended experience), (b) explore EEG correlates of these experiences in the two states, and (c) describe their phenomenology (what they are like). We will also examine short-term changes in well-being and sleep related to these experiences. Participants complete four sessions (two of each method) with EEG and routine monitoring, immediate post-session interviews, and brief questionnaires and daily sleep/dream logs before and after anesthesia sessions.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Propofol - Emergence-from-LOR Protocol

Intravenous propofol infusion that meets the criteria: (1) maintenance of spontaneous ventilation, (2) sedation level corresponding to a Patient State Index (PSI) no lower than 25; and (3) loss of responsiveness (LOR) defined by the Richmond Agitation Sedation Scale (RASS) = -5 \[unarousable\]. Anesthesia is then maintained at that level for 30 minutes, followed by spontaneous emergence.

DRUG

Propofol - Light Sedation Protocol

Intravenous propofol infusion titrated stepwise to reach a state where participants are sedated but have behavioral responsiveness. Sedation is maintained at this level for 30 minutes.

Sponsors & Collaborators

Principal Investigators

  • Dr. Boris D Heifets, MD, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-20
Primary Completion
2026-05-31
Completion
2026-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07198711 on ClinicalTrials.gov